(Q36008673)

11 August 2017

1 reference

title

Novel pharmacological approaches in the treatment of psoriasis (English)

1 reference

11 August 2017

Schleyer V

1

1 reference

11 August 2017

Landthaler M

series ordinal

2

1 reference

11 August 2017

Szeimies RM

series ordinal

3

1 reference

11 August 2017

publication date

1 January 2005

1 reference

Journal of the European Academy of Dermatology and Venereology

11 August 2017

published in

1 reference

11 August 2017

volume

19

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

1-20

1 reference

The inflammatory infiltrate in psoriasis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Psoriasis--epidemiology and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Use of cyclosporin in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Functional diversity of helper T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Genetic aspects of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Mycophenolic acid in the treatment of psoriasis: long-term administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Treatment of severe psoriasis and psoriatic arthritis with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Leflunomide--a new drug for pharmacological immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Recombinantly engineered human proteins: transforming the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Regulation of the human interleukin-2/interleukin-2 receptor system: a role for immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

The mechanism of action of cyclosporin A and FK506

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tacrolimus in dermatologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tacrolimus: the drug for the turn of the millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tacrolimus ointment improves psoriasis in a microplaque assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Retinoic acid receptor-nuclear factor-interleukin 6 antagonism. A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Tazarotene plus UVB phototherapy in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Novel treatment of chronic severe hand dermatitis with bexarotene gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Treatment of psoriasis with oral liarozole: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01070.X

10.1111/J.1468-3083.2004.01070.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference